Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRECCAR 15: Chemotherapy with pelvic reirradiation vs chemotherapy alone for locally recurrent rectal cancer
2024-514705-62-00Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Jul 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of camptothecin, folinic acid, fluorouracil, oxaliplatin and capecitabine in rectal cancer (2 arms), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Proportion of curative surgery (R0 resection). Started Jul 2024; status: completed.
02
Drugs
camptothecinfolinic acidfluorouraciloxaliplatincapecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2024-514705-62-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514705-62-00.